These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

235 related items for PubMed ID: 15497466

  • 1. In vitro inhibition of fibrinolysis by apolipoprotein(a) and lipoprotein(a) is size- and concentration-dependent.
    Knapp JP, Herrmann W.
    Clin Chem Lab Med; 2004; 42(9):1013-9. PubMed ID: 15497466
    [Abstract] [Full Text] [Related]

  • 2. Inhibition of fibrinolysis by lipoprotein(a).
    Anglés-Cano E, de la Peña Díaz A, Loyau S.
    Ann N Y Acad Sci; 2001; 936():261-75. PubMed ID: 11460483
    [Abstract] [Full Text] [Related]

  • 3. Antifibrinolytic effect of single apo(a) kringle domains: relationship to fibrinogen binding.
    Rahman MN, Petrounevitch V, Jia Z, Koschinsky ML.
    Protein Eng; 2001 Jun; 14(6):427-38. PubMed ID: 11477223
    [Abstract] [Full Text] [Related]

  • 4. Influence of lipoprotein (a) levels and isoforms on fibrinolytic activity--study in families with high lipoprotein (a) levels.
    Falcó C, Estellés A, Dalmau J, España F, Aznar J.
    Thromb Haemost; 1998 Apr; 79(4):818-23. PubMed ID: 9580386
    [Abstract] [Full Text] [Related]

  • 5. Does apolipoprotein(a) heterogeneity influence lipoprotein(a) effects on fibrinolysis?
    Hervio L, Chapman MJ, Thillet J, Loyau S, Anglés-Cano E.
    Blood; 1993 Jul 15; 82(2):392-7. PubMed ID: 8329699
    [Abstract] [Full Text] [Related]

  • 6. Effects of lipoprotein(a) on the binding of plasminogen to fibrin and its activation by fibrin-bound tissue-type plasminogen activator.
    Anglés-Cano E, Hervio L, Rouy D, Fournier C, Chapman JM, Laplaud M, Koschinsky ML.
    Chem Phys Lipids; 1994 Jan 15; 67-68():369-80. PubMed ID: 8187237
    [Abstract] [Full Text] [Related]

  • 7. Molecular cloning of the cDNA encoding the carboxy-terminal domain of chimpanzee apolipoprotein(a): an Asp57 --> Asn mutation in kringle IV-10 is associated with poor fibrin binding.
    Chenivesse X, Huby T, Wickins J, Chapman J, Thillet J.
    Biochemistry; 1998 May 19; 37(20):7213-23. PubMed ID: 9585533
    [Abstract] [Full Text] [Related]

  • 8. Antifibrinolytic effect of recombinant apolipoprotein(a) in vitro is primarily due to attenuation of tPA-mediated Glu-plasminogen activation.
    Sangrar W, Bajzar L, Nesheim ME, Koschinsky ML.
    Biochemistry; 1995 Apr 18; 34(15):5151-7. PubMed ID: 7711034
    [Abstract] [Full Text] [Related]

  • 9. The solution phase interaction between apolipoprotein(a) and plasminogen inhibits the binding of plasminogen to a plasmin-modified fibrinogen surface.
    Sangrar W, Gabel BR, Boffa MB, Walker JB, Hancock MA, Marcovina SM, Horrevoets AJ, Nesheim ME, Koschinsky ML.
    Biochemistry; 1997 Aug 26; 36(34):10353-63. PubMed ID: 9265615
    [Abstract] [Full Text] [Related]

  • 10. Beyond fibrinolysis: The confounding role of Lp(a) in thrombosis.
    Boffa MB.
    Atherosclerosis; 2022 May 26; 349():72-81. PubMed ID: 35606079
    [Abstract] [Full Text] [Related]

  • 11. Mechanism for the homocysteine-enhanced antifibrinolytic potential of lipoprotein(a) in human plasma.
    Nardulli M, Durlach V, Pepe G, Anglés-Cano E.
    Thromb Haemost; 2005 Jul 26; 94(1):75-81. PubMed ID: 16113787
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Lipoprotein(a): a genetically determined lipoprotein containing a glycoprotein of the plasminogen family.
    Scanu AM.
    Semin Thromb Hemost; 1988 Jul 26; 14(3):266-70. PubMed ID: 2972066
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Lipoprotein(a) impairs generation of plasmin by fibrin-bound tissue-type plasminogen activator. In vitro studies in a plasma milieu.
    Rouy D, Grailhe P, Nigon F, Chapman J, Anglés-Cano E.
    Arterioscler Thromb; 1991 Jul 26; 11(3):629-38. PubMed ID: 1827591
    [Abstract] [Full Text] [Related]

  • 17. Apolipoprotein(a) and plasminogen interactions with fibrin: a study with recombinant apolipoprotein(a) and isolated plasminogen fragments.
    Rouy D, Koschinsky ML, Fleury V, Chapman J, Anglés-Cano E.
    Biochemistry; 1992 Jul 14; 31(27):6333-9. PubMed ID: 1627572
    [Abstract] [Full Text] [Related]

  • 18. Characterization of the interaction of recombinant apolipoprotein(a) with modified fibrinogen surfaces and fibrin clots.
    Sangrar W, Koschinsky ML.
    Biochem Cell Biol; 2000 Jul 14; 78(4):519-25. PubMed ID: 11012092
    [Abstract] [Full Text] [Related]

  • 19. Comparison of the effects of Apo(a) kringle IV-10 and plasminogen kringles on the interactions of lipoprotein(a) with regulatory molecules.
    Xue S, Green MA, LoGrasso PV, Boettcher BR, Madison EL, Curtiss LK, Miles LA.
    Thromb Haemost; 1999 Mar 14; 81(3):428-35. PubMed ID: 10102473
    [Abstract] [Full Text] [Related]

  • 20. Lipoprotein (a) regulates plasmin generation and inhibition.
    Edelberg J, Pizzo SV.
    Chem Phys Lipids; 1994 Jan 14; 67-68():363-8. PubMed ID: 8187236
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 12.